Biology and therapy of chronic myelogenous leukemia:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
1998
|
| Schriftenreihe: | Hematology, oncology clinics of North America
12,1 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XII, 211 S. Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV011832215 | ||
| 003 | DE-604 | ||
| 005 | 20150203 | ||
| 007 | t | ||
| 008 | 980317s1998 ad|| |||| 00||| eng d | ||
| 035 | |a (OCoLC)247590383 | ||
| 035 | |a (DE-599)BVBBV011832215 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-355 |a DE-12 |a DE-29 |a DE-578 | ||
| 084 | |a YC 1700 |0 (DE-625)153192: |2 rvk | ||
| 245 | 1 | 0 | |a Biology and therapy of chronic myelogenous leukemia |c Philip McGlave ... guest ed. |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 1998 | |
| 300 | |a XII, 211 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Hematology, oncology clinics of North America |v 12,1 | |
| 650 | 0 | 7 | |a Chronisch-myeloische Leukämie |0 (DE-588)4199205-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Chronisch-myeloische Leukämie |0 (DE-588)4199205-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a McGlave, Philip |d 1947- |e Sonstige |0 (DE-588)17318359X |4 oth | |
| 830 | 0 | |a Hematology, oncology clinics of North America |v 12,1 |w (DE-604)BV000625446 |9 12,1 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007990402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-007990402 | ||
Datensatz im Suchindex
| _version_ | 1804126376002846720 |
|---|---|
| adam_text | BIOLOGY THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
CONTENTS
Preface xi
Philip McGlave and Catherine M. Verfaillie
Biology of Chronic Myelogenous Leukemia 1
Catherine M. Verfaillie
This article reviews the biology of chronic myelogenous leukemia
(CML) and its effect on the process of hematopoiesis. The rele¬
vance of the BCR ABL fusion protein as well as murine models
are also discussed. CML has been studied more extensively than
any other malignancy, yet the correlation between the clinical
symptoms of chronic phase CML and the BCR ABL oncoprotein
is poorly understood. Insights from recent efforts both to develop
a good in vivo animal model and to characterize the effect of the
BCR ABL oncoprotein on relevant signal molecules may lead to
a better understanding of the pathophysiology of chronic phase
CML and, thereby, to the development of targeted therapeutic
approaches.
Clinical Course and Therapy of Chronic Myelogenous
Leukemia with Interferon Alpha and Chemotherapy 31
Hagop M. Kantarjian, Francis J. Giles, Susan M. O Brien, and
Moshe Talpaz
This article begins with a review of the natural history of chronic
myelogenous leukemia (CML), with an emphasis on prognostic
features. Current standard therapy of CML with interferon alpha
based regimens, and interferon alpha, in the context of allogenic
stem cell transplantation is then discussed. Finally, some poten¬
tially effective novel agents including homoharringtonine, deci
tabine, ATRA, and topotecan are described.
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA
VOLUME 12 • NUMBER 2 • FEBRUARY 1998 V
Related Donor Bone Marrow Transplantation for Chronic
Myelogenous Leukemia 81
Jakob R. Passweg, Philip A. Rowlings, and
Mary M. Horowitz
HLA identical sibling bone marrow transplantation is an effective
and commonly used therapy for young patients with chronic
myelogenous leukemia. Efficacy results from high dose chemo¬
therapy, with or without radiation, given for pretransplant condi¬
tioning and from immune mediated antileukemia effects of the
graft. The primary determinant of outcome is the patient s disease
phase at time of transplant, with best results observed when
transplants are done early in the chronic phase. Major causes of
treatment failure are graft versus host disease and other trans¬
plant related complications. Relatively few patients relapse unless
the disease is advanced pretransplant or the donor bone marrow
is T cell depleted.
Unrelated Donor Transplant Therapy for Chronic
Myelogenous Leukemia 93
Philip McGlave
Unrelated donor transplant therapy for chronic myelogenous leu¬
kemia is both feasible and effective. As discussed in this article,
clinical outcome can be predicted based on several patient charac¬
teristics and transplant conditions. Highly selected subsets of
patients experience outcomes not appreciably different from re¬
cipients of related donor transplants. In many cases, however,
unrelated donor transplant is associated with significant peritran
splant mortality and other complications. The impact of recent
improvements in donor recipient typing, marrow procurement,
graft versus host disease prevention and treatment, medical sup¬
port, and donor selection should soon become apparent.
Effect of HLA Matching on Outcome of Related and
Unrelated Donor Transplantation Therapy for Chronic
Myelogenous Leukemia 107
Effie Petersdorf, Claudio Anasetti, Paolo Servida,
Paul Martin, and John Hansen
This article examines the diversity and biologic role of human
lymphocyte antigen (HLA) genes as related to marrow trans¬
plantation for chronic myelogenous leukemia (CML). A better
understanding of the nature and function of HLA variation is
necessary as unrelated marrow transplantation evolves into a safe
and effective treatment for CML. HLA matching is an important
aspect of donor selection criteria and has a role in engraftment as
well as the development of graft versus host disease and toler¬
ance after transplant.
Vi CONTENTS
Infusion of Donor Peripheral Blood Mononuclear Cells to
Treat Relapse After Transplantation for Chronic
Myelogenous Leukemia 123
David L. Porter and Joseph H. Antin
Until recently, the only curative therapy for patients with chronic
myelogenous leukemia (CML) who relapse after allogeneic bone
marrow transplantation (BMT) has been second allogeneic BMT.
Recently, donor mononuclear cells have been given to patients
with relapsed CML to induce a potent graft versus leukemia reac¬
tion and re establish complete remissions in the majority of pa¬
tients without the need for a second transplant. The extraordinary
success of donor mononuclear cell infusions shows that it is
possible to manipulate and harness the graft versus leukemia
(GVL) reaction for clinical benefit. The identity of the effector
cells and target antigens is unclear, but intensive investigation is
beginning to define the complex cytokine and cellular interactions
that mediate GVL reactivity. Current clinical trials are investigat¬
ing strategies that will retain and enhance the GVL effects while
limiting toxicity from this therapy. Ultimately, the ability to har¬
ness the GVL potential of allogeneic donor cells without excessive
toxicity from graft versus host disease will be a central challenge
in BMT and cellular immunotherapy.
Autologous Transplantation for the Treatment of Chronic
Myelogenous Leukemia 151
Ravi Bhatia and Stephen J. Forman
There is evidence that benign, Ph negative hematopoietic progen¬
itors persist in the marrow and blood of some patients with
chronic myelogenous leukemia (CML). A number of pilot studies
using purged and unpurged marrow or peripheral blood auto
grafts have demonstrated that autologous transplantation can
result in transient cytogenetic responses in CML. Although not
curative, this procedure may be associated with longer than ex
pected patient survival and represents an alternative treatment
for patients ineligible for allogeneic transplantation and not re¬
sponding to interferon alpha therapy. Several novel approaches
are being developed to improve graft purging and eliminate
residual leukemia post transplantation. Such approaches may
allow for long term restoration of Ph negative hematopoiesis fol¬
lowing the procedure.
Innovative Therapy for Chronic Myelogenous Leukemia 173
Jeffrey S. Miller
Innovative therapies for chronic myelogenous leukemia (CML)
have focused mainly on combining autologous transplantation
with another modality of therapy for purging of the graft or
treatment of the patient after transplant. Of the three categories
of innovative therapies, two are based on studies that demon¬
strate the bcr/abl gene rearrangement in the pathogenesis of CML,
whereas the third is based on the observation that allogeneic
CONTENTS Vii
disparity is important to maintain remissions in CML. The ratio¬
nale and data supporting these innovative approaches are re¬
viewed in this article and future strategies are discussed.
Index 207
Subscription Information Inside back cover
viii CONTENTS
|
| any_adam_object | 1 |
| author_GND | (DE-588)17318359X |
| building | Verbundindex |
| bvnumber | BV011832215 |
| classification_rvk | YC 1700 |
| ctrlnum | (OCoLC)247590383 (DE-599)BVBBV011832215 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01451nam a2200337 cb4500</leader><controlfield tag="001">BV011832215</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150203 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">980317s1998 ad|| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)247590383</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011832215</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 1700</subfield><subfield code="0">(DE-625)153192:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biology and therapy of chronic myelogenous leukemia</subfield><subfield code="c">Philip McGlave ... guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII, 211 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">12,1</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chronisch-myeloische Leukämie</subfield><subfield code="0">(DE-588)4199205-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Chronisch-myeloische Leukämie</subfield><subfield code="0">(DE-588)4199205-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McGlave, Philip</subfield><subfield code="d">1947-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)17318359X</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">12,1</subfield><subfield code="w">(DE-604)BV000625446</subfield><subfield code="9">12,1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007990402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007990402</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV011832215 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:16:28Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007990402 |
| oclc_num | 247590383 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-12 DE-29 DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-12 DE-29 DE-578 |
| physical | XII, 211 S. Ill., graph. Darst. |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Saunders |
| record_format | marc |
| series | Hematology, oncology clinics of North America |
| series2 | Hematology, oncology clinics of North America |
| spelling | Biology and therapy of chronic myelogenous leukemia Philip McGlave ... guest ed. Philadelphia [u.a.] Saunders 1998 XII, 211 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Hematology, oncology clinics of North America 12,1 Chronisch-myeloische Leukämie (DE-588)4199205-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Chronisch-myeloische Leukämie (DE-588)4199205-2 s DE-604 McGlave, Philip 1947- Sonstige (DE-588)17318359X oth Hematology, oncology clinics of North America 12,1 (DE-604)BV000625446 12,1 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007990402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Biology and therapy of chronic myelogenous leukemia Hematology, oncology clinics of North America Chronisch-myeloische Leukämie (DE-588)4199205-2 gnd |
| subject_GND | (DE-588)4199205-2 (DE-588)4143413-4 |
| title | Biology and therapy of chronic myelogenous leukemia |
| title_auth | Biology and therapy of chronic myelogenous leukemia |
| title_exact_search | Biology and therapy of chronic myelogenous leukemia |
| title_full | Biology and therapy of chronic myelogenous leukemia Philip McGlave ... guest ed. |
| title_fullStr | Biology and therapy of chronic myelogenous leukemia Philip McGlave ... guest ed. |
| title_full_unstemmed | Biology and therapy of chronic myelogenous leukemia Philip McGlave ... guest ed. |
| title_short | Biology and therapy of chronic myelogenous leukemia |
| title_sort | biology and therapy of chronic myelogenous leukemia |
| topic | Chronisch-myeloische Leukämie (DE-588)4199205-2 gnd |
| topic_facet | Chronisch-myeloische Leukämie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007990402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625446 |
| work_keys_str_mv | AT mcglavephilip biologyandtherapyofchronicmyelogenousleukemia |